Orthocell Ltd ( ASX: OCC ) share price is catching the eye of investors on Monday.

In late afternoon trade, the regenerative medicine company's shares are up over 10% to $1.37.

This means that Orthocell shares are now up approximately 250% since this time last year.

Orthocell is a regenerative medicine company with a focus on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries.

Its portfolio includes the CelGro platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications.

Striate+ was the first product approved for dental GBR applications, and is distributed globally by BioHorizons Implant Systems Inc. It is cleared for use in the US, Canada, Australia, New Zealand, the UK, and Europe.

SmrtGraft is for tendon repair and is available in Australia under Special Access Scheme or participation in a clinical trial.